Nanocarriers for vascular delivery of antioxidants

Nanomedicine

Volumn 6, Issue 7, 2011, Pages 1257-1272

  Hood, Elizabeth ^a   Simone, Eric ^b   Wattamwar, Paritosh ^c   Dziubla, Thomas ^c   Muzykantov, Vladimir ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

antioxidant enzymes; catalase; liposomes; magnetic nanoparticles; oxidative stress; polymer nanocarrier; SOD; vascular immunotargeting

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BETA TOCOPHEROL; BUTYLCRESOL; CATALASE; CATECHIN; CURCUMIN; FISETIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; ISOFLAVONE DERIVATIVE; LIPOSOMAL ACETYLCYSTEINE; LIPOSOMAL SUPEROXIDE DISMUTASE; LIPOSOME; LYCOPENE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; POLY(TROLOX ESTER); POLYMER; QUERCETIN; RESVERATROL; RETINOL; SUPEROXIDE DISMUTASE; TROLOX C; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; BLOOD VESSEL INJURY; BRAIN INJURY; CARDIOVASCULAR SYSTEM; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SYNTHESIS; DRUG UPTAKE; EMULSION; FREEZE THAWING; HEART MUSCLE ISCHEMIA; HYPEROXIA; HYPERTENSION; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LIVER INJURY; LUNG; LUNG INJURY; LYSOSOME; MACROPHAGE; MICELLE; MOLECULAR SIZE; NANODEVICE; NANOTECHNOLOGY; NERVOUS SYSTEM; NONHUMAN; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; REPERFUSION INJURY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; CATALASE; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; NANOSTRUCTURES; SUPEROXIDE DISMUTASE;

EID: 80053109906     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.92     Document Type: Review

References (162)

1. Christofidou-Solomidou M, Muzykantov VR. Antioxidant strategies in respiratory medicine. Treat. Respir. Med. 5(1), 47-78 (2006). (Pubitemid 43116813)
2. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. J. Control. Release 71(1), 1-21 (2001). (Pubitemid 32195437)
3. Yi X, Zimmerman MC, Yang R, Tong J, Vinogradov S, Kabanov AV. Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons. Free Radic. Biol. Med. 49(4), 548-558 (2010).
4. Muzykantov VR. Delivery of antioxidant enzyme proteins to the lung. Antioxid. Redox Signal. 3(1), 39-62 (2001). (Pubitemid 32240628)
5. Suarna C, Wu BJ, Choy K et al. Protective effect of vitamin E supplements on experimental atherosclerosis is modest and depends on preexisting vitamin E deficiency. Free Radic. Biol. Med. 41(5), 722-730 (2006). (Pubitemid 44177661)
6. Siekmeier R, Steffen C, Marz W. Role of oxidants and antioxidants in atherosclerosis: results of in vitro and in vivo investigations. J. Cardiovasc. Pharmacol. Ther. 12(4), 265-282 (2007). (Pubitemid 350264698)
7. Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc. Drugs Ther. 21(3), 195-210 (2007). (Pubitemid 46817482)
8. Dziubla TD, Muro S, Muzykantov VR, Koval M. Nanoscale antioxidant therapeutics. In: Oxidative Stress, Disease and Cancer. Singh KK (Ed.).Imperial College Press, London, UK (2006).
9. Delles C, Miller WH, Dominiczak AF. Targeting reactive oxygen species in hypertension. Antioxid. Redox Signal. 10(6), 1061-1077 (2008). (Pubitemid 351451714)
10. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J. Control. Release 113(3), 189-207 (2006). (Pubitemid 43983041)
11. Muzykantov VR, Atochina EN, Ischiropoulos H, Danilov SM, Fisher AB. Immunotargeting of antioxidant enzyme to the pulmonary endothelium. Proc. Natl Acad. Sci. USA 93(11), 5213-5218 (1996). (Pubitemid 26159428)
12. Muzykantov VR, Christofidou-Solomidou M, Balyasnikova I et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl Acad. Sci. USA 96(5), 2379-2384 (1999). (Pubitemid 29117923)
13. Nowak K, Weih S, Metzger R et al. Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. Am. J. Physiol. Lung Cell Mol. Physiol. 293(1), L162-L169 (2007). (Pubitemid 47080724)
14. Shuvaev VV, Tliba S, Nakada M, Albelda SM, Muzykantov VR. Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J. Pharmacol. Exp. Ther. 323(2), 450-457 (2007). (Pubitemid 350005112)
15. Shuvaev VV, Christofidou-Solomidou M, Bhora F et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J. Pharmacol. Exp. Ther. 331(2), 404-411 (2009).
16. Shuvaev VV, Han J, Yu KJ et al. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 25(1), 348-357 (2010).
17. Kozower BD, Christofidou-Solomidou M, Sweitzer TD et al. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat. Biotechnol. 21(4), 392-398 (2003). (Pubitemid 36397659)
18. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am. J. Physiol. Lung Cell Mol. Physiol. 285(2), L283-292 (2003). (Pubitemid 36909443)
19. Muro S, Wiewrodt R, Thomas A et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116(Pt 8), 1599-1609 (2003). (Pubitemid 36527505)
20. Wiewrodt R, Thomas AP, Cipelletti L et al. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 99(3), 912-922 (2002). (Pubitemid 34525553)
21. Muro S, Cui X, Gajewski C, Murciano JC, Muzykantov VR, Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am. J. Physiol. Cell Physiol. 285(5), C1339-C1347 (2003). (Pubitemid 37296311)
22. Muro S, Gajewski C, Koval M, Muzykantov VR. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 105(2), 650-658 (2005). (Pubitemid 40070749)
23. Stenesh J. Biochemistry. Plenum, NY, USA (1998).
24. Papi A, Chicca M, Pandit A, Caramori G, Geoffrey JL, Steven DS. Oxidants and antioxidants/ Antioxidants, Nonenzymatic. In: Encyclopedia of Respiratory Medicine. Academic Press, Oxford, UK, 266-271 (2006).
25. Quideau S, Deffieux D, Douat-Casassus C, Pouysegu L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem. Int. Ed. Engl. 50(3), 586-621 (2011).
26. Sandur SK, Ichikawa H, Pandey MK et al. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane).Free Radic. Biol. Med. 43(4), 568-580 (2007). (Pubitemid 47058232)
27. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and liver cancer: a review. Curr. Pharm. Biotechnol. (2011) (Epub ahead of print).
28. Pezzuto JM. The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann. NY Acad. Sci. 1215(1), 123-130 (2011).
29. Freeman BA, Young SL, Crapo JD. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J. Biol. Chem. 258(20), 12534-12542 (1983). (Pubitemid 14231172)
30. Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J. Control. Release 146(1), 144-151 (2010).
31. Batrakova EV, Li S, Reynolds AD et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug. Chem. 18(5), 1498-1506 (2007). (Pubitemid 47464057)
32. Vertegel AA, Reukov V, Maximov V. Enzyme-nanoparticle conjugates for biomedical applications. Methods Mol. Biol. 679, 165-182 (2011).
33. Nagami H, Yoshimoto N, Umakoshi H, Shimanouchi T, Kuboi R. Liposome-assisted activity of superoxide dismutase under oxidative stress. J. Biosci. Bioeng. 99(4), 423-428 (2005). (Pubitemid 40740595)
34. Stone WL, Smith M. Therapeutic uses of antioxidant liposomes. Mol. Biotechnol. 27(3), 217-230 (2004). (Pubitemid 41490590)
35. Gonnet M, Lethuaut L, Boury F. New trends in encapsulation of liposoluble vitamins. J. Control. Release 146(3), 276-290 (2010).
36. Alipour M, Omri A, Smith MG, Suntres ZE. Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J. Endo. Res. 13(5), 297-304 (2007). (Pubitemid 350056225)
37. Mitsopoulos P, Omri A, Alipour M, Vermeulen N, Smith MG, Suntres ZE. Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int. J. Pharma. 363(1-2), 106-111 (2008).
38. Fan J, Shek PN, Suntres ZE, Li YH, Oreopoulos GD, Rotstein OD. Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome. Surgery 128(2), 332-338 (2000). (Pubitemid 30622502)
39. Mukhopadhyay S, Mukherjee S, Stone WL, Smith M, Das SK. Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome. Toxicology 261(3), 143-151 (2009).
40. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug-delivery systems of curcumin for cancer chemoprevention. Cancer Prev. Res. (Phila).4(8), 1158-1171 (2011).
41. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol. 32(5), 1119-1123 (2008).
42. Hung CF, Chen JK, Liao MH, Lo HM, Fang JY. Development and evaluation of emulsion-liposome blends for resveratrol delivery. J. Nanosci. Nanotechnol. 6(9-10), 2950-2958 (2006).
43. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125(1), 1-8 (2009).
44. Williams SR, Lepene BS, Thatcher CD, Long TE. Synthesis and characterization of poly(ethylene glycol)-glutathione conjugate self-assembled nanoparticles for antioxidant delivery. Biomacromolecules 10(1), 155-161 (2009).
45. Tanswell AK, Freeman BA. Liposome-entrapped antioxidant enzymes prevent lethal O2 toxicity in the newborn rat. J. Appl. Physiol. 63(1), 347-352 (1987). (Pubitemid 17107166)
46. Briscoe P, Caniggia I, Graves A et al. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am. J. Physiol. 268(3 Pt 1), L374-380 (1995).
47. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95(3), 588-593 (1997). (Pubitemid 27063033)
48. Corvo LM, Jorge JCS, van't Hof R, Cruz MEM, Crommelin DJA, Storm G. Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim. Biophys. Acta 1564(1), 227-236 (2002). (Pubitemid 34717889)
49. Gaspar MM, Martins MB, Corvo ML, Cruz ME. Design and characterization of enzymosomes with surface-exposed superoxide dismutase. Biochim. Biophys. Acta 1609(2), 211-217 (2003). (Pubitemid 36120729)
50. Gaspar MM, Boerman OC, Laverman P, Corvo ML, Storm G, Cruz ME. Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J. Control. Release 117(2), 186-195 (2007). (Pubitemid 46172500)
51. Brynskikh AM, Zhao Y, Mosley RL et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine 5(3), 379-396 (2010).
52. Rosenbaugh EG, Roat JW, Gao L et al. The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials 31(19), 5218-5226 (2010).
53. Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16(9), 1366-1372 (1999). (Pubitemid 29449372)
54. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296(2), 551-557 (2001). (Pubitemid 32112485)
55. Batrakova EV, Zhang Y, Li Y et al. Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood-brain barrier. Pharm. Res. 21(11), 1993-2000 (2004). (Pubitemid 40941218)
56. Chorny M, Fishbein I, Alferiev I, Levy RJ. Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. Mol. Pharm. 6(5), 1380-1387 (2009).
57. Shuvaev VV, Tliba S, Pick J et al. Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J. Control. Release 149(3), 236-241 (2011).
58. Villano D, Fernandez-Pachon MS, Moya ML, Troncoso AM, Garcia-Parrilla MC. Radical scavenging ability of polyphenolic compounds towards DPPH free radical. Talanta 71(1), 230-235 (2007). (Pubitemid 46038394)
59. Rock CL, Jacob RA, Bowen PE. Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. J. Am. Diet Assoc. 96(7), 693-702; quiz 703-694 (1996). (Pubitemid 126449545)
60. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans. 35(Pt 5), 1156-1160 (2007). (Pubitemid 350206449)
61. Wattamwar PP, Hardas SS, Butterfield DA, Anderson KW, Dziubla TD. Tuning of the pro-oxidant and antioxidant activity of trolox through the controlled release from biodegradable poly(trolox ester) polymers. Acta Biomaterialia (2011) (In Press).
62. Kumar V, Prud'Homme RK. Thermodynamic limits on drug loading in nanoparticle cores. J. Pharm. Sci. 97(11), 4904-4914 (2008).
63. De Villiers MM, Aramwit P, Kwon GS. Nanotechnology in Drug Delivery. Springer, AAPS Press, NY and VA, USA (2009).
64. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263(5153), 1600-1603 (1994). (Pubitemid 24128361)
65. Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr. Med. Chem. 17(1), 74-95).
66. Kumar V, Hong SY, Maciag AE et al. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles. Mol. Pharm. 7(1), 291-298 (2010).
67. Wattamwar PP, Mo YQ, Wan R, Palli R, Zhang QW, Dziubla TD. Antioxidant activity of degradable polymer poly(trolox ester) to suppress oxidative stress injury in the cells. Adv. Func. Mater. 20(1), 147-154 (2010).
68. Fleming C, Maldjian A, Da Costa D et al. A carbohydrate-antioxidant hybrid polymer reduces oxidative damage in spermatozoa and enhances fertility. Nat. Chem. Biol. 1(5), 270-274 (2005).
69. Spizzirri UG, Iemma F, Puoci F et al. Synthesis of antioxidant polymers by grafting of gallic acid and catechin on gelatin. Biomacromolecules 10(7), 1923-1930 (2009).
70. Wang Y, Singh A, Xu P, Pindrus MA, Blasioli DJ, Kaplan DL. Expansion and osteogenic differentiation of bone marrow-derived mesenchymal stem cells on a vitamin C functionalized polymer. Biomaterials 27(17), 3265-3273 (2006). (Pubitemid 43344338)
71. Dziubla TD, Karim A, Muzykantov VR. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control. Release 102(2), 427-439 (2005). (Pubitemid 40093764)
72. Giovagnoli S, Luca G, Casaburi I et al. Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: In vitro effects on isolated neonatal porcine pancreatic cell clusters. J. Control. Release 107(1), 65-77 (2005). (Pubitemid 41253703)
73. Seshadri G, Sy JC, Brown M et al. The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury. Biomaterials 31(6), 1372-1379 (2010).
74. Fiore VF, Lofton MC, Roser-Page S et al. Polyketal microparticles for therapeutic delivery to the lung. Biomaterials 31(5), 810-817 (2010).
75. Dziubla TD, Shuvaev VV, Hong NK et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 29(2), 215-227 (2008). (Pubitemid 350017841)
76. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl. Biochem. Biotechnol. 151(2-3), 565-577 (2008).
77. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 23(5), 1384-1395 (2009).
78. Muro S, Dziubla T, Qiu W et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 317(3), 1161-1169 (2006). (Pubitemid 43764121)
79. Yan M, Du JJ, Gu Z et al. A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat. Nanotechnol. 5(1), 48-53 (2010).
80. Kim D, Kim E, Kim J et al. Direct synthesis of polymer nanocapsules with a noncovalently tailorable surface. Angew. Chem. Int. Ed. 46(19), 3471-3474 (2007). (Pubitemid 46973433)
81. Kim E, Kim D, Jung H et al. Facile, Template-Free Synthesis of Stimuli-Responsive Polymer Nanocapsules for Targeted Drug Delivery. Angew. Chem. Int. Ed. 49(26), 4405-4408 (2010).
82. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J. Control. Release 90(3), 323-334 (2003). (Pubitemid 36859964)
83. Saad M, Garbuzenko OB, Ber E et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J. Control. Release 130(2), 107-114 (2008).
84. Dziubla TD, Karim A, Muzykantov VR. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control. Release 102(2), 427-439 (2005). (Pubitemid 40093764)
85. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J. Control. Release 96(1), 37-53 (2004). (Pubitemid 38438488)
86. Zarif L. Elongated supramolecular assemblies in drug delivery. J. Control. Release 81(1-2), 7-23 (2002). (Pubitemid 34460570)
87. Bianco A, Kostarelos K, Prato M. Opportunities and challenges of carbon-based nanomaterials for cancer therapy. Expert Opin. Drug Deliv. 5(3), 331-342 (2008). (Pubitemid 351454382)
88. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
89. Muro S, Garnacho C, Champion JA et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 16(8), 1450-1458 (2008).
90. Xu S, Nie Z, Seo M et al. Generation of monodisperse particles by using microfluidics: control over size, shape, and composition. Angew. Chem. Int. Ed. Engl. 44(5), 724-728 (2005). (Pubitemid 40203980)
91. Dendukuri D, Pregibon DC, Collins J, Hatton TA, Doyle PS. Continuous-flow lithography for high-throughput microparticle synthesis. Nat. Mater. 5(5), 365-369 (2006).
92. Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM. Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J. Control. Release 121(1-2), 10-18 (2007). (Pubitemid 47126067)
93. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127(28), 10096-10100 (2005). (Pubitemid 40995455)
94. Gratton SE, Napier ME, Ropp PA, Tian S, Desimone JM. Microfabricated particles for engineered drug therapies: elucidation into the mechanisms of cellular internalization of PRINT particles. Pharm. Res. 25(12), 2845-2852 (2008).
95. Lee JC, Bermudez H, Discher BM et al. Preparation, stability, and in vitro performance of vesicles made with diblock copolymers. Biotechnol. Bioeng. 73(2), 135-145 (2001). (Pubitemid 32291402)
96. Discher DE, Eisenberg A. Polymer vesicles. Science 297(5583), 967-973 (2002). (Pubitemid 34856022)
97. Lee JC, Wong DT, Discher DE. Direct measures of large, anisotropic strains in deformation of the erythrocyte cytoskeleton. Biophys. J. 77(2), 853-864 (1999). (Pubitemid 29362457)
98. Dalhaimer P, Bates FS, Discher DE. Single molecule visualization of stable, stiffness-tunable, flow-conforming worm micelles. Macromolecules 36(18), 6873-6877 (2003).
99. Simone EA, Dziubla TD, Colon-Gonzalez F, Discher DE, Muzykantov VR. Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 8(12), 3914-3921 (2007).
100. Simone EA, Dziubla TD, Discher DE, Muzykantov VR. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules 10(6), 1324-1330 (2009).
101. Petros RA, Ropp PA, DeSimone JM. Reductively labile PRINT particles for the delivery of doxorubicin to HeLa cells. J. Am. Chem. Soc. 130(15), 5008-5009 (2008). (Pubitemid 351537040)
102. Kelly JY, DeSimone JM. Shape-specific, monodisperse nano-molding of protein particles. J. Am. Chem. Soc. 130(16), 5438-5439 (2008). (Pubitemid 351612948)
103. Castillo J, Curley J, Hotz J et al. Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology 85(5), 1157-1166 (1996). (Pubitemid 26378302)
104. Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 23(7), 1649-1656 (2002). (Pubitemid 34158587)
105. Simone EA, Dziubla TD, Arguiri E et al. Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm. Res. 26(1), 250-260 (2009).
106. Kumar N, Ravikumar MN, Domb AJ. Biodegradable block copolymers. Adv. Drug Deliv. Rev. 53(1), 23-44 (2001). (Pubitemid 33152832)
107. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28(1), 5-24 (1997). (Pubitemid 27497671)
108. Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv. Drug Deliv. Rev. 48(2-3), 229-247 (2001). (Pubitemid 32434405)
109. Hanes J, Chiba M, Langer R. Synthesis and characterization of degradable anhydride-co-imide terpolymers containing trimellitylimido-l-tyrosine: novel polymers for drug delivery. Macromolecules 29(16), 5279-5287 (1996). (Pubitemid 126548728)
110. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J. Biomed. Mater. Res. 19(8), 941-955 (1985). (Pubitemid 16257502)
111. Tabata Y, Gutta S, Langer R. Controlled delivery systems for proteins using polyanhydride microspheres. Pharm. Res. 10(4), 487-496 (1993). (Pubitemid 23113038)
112. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. Release 65(1-2), 261-269 (2000). (Pubitemid 30122931)
113. Fu J, Wu C. Laser light scattering of the degradation of poly(sebacic anhydride) nanoparticles. J. Polymer Sci. B Polymer Phys. 39(6), 703-708 (2001). (Pubitemid 32253829)
114. Pfeifer BA, Burdick JA, Langer R. Formulation and surface modification of poly(ester-anhydride) micro-and nanospheres. Biomaterials 26(2), 117-124 (2005). (Pubitemid 38789094)
115. Li S, Garreau H, Vert M. Structure-property relationships in the case of the degradation of solid aliphatic poly-(α-hydroxy acids) in aqueous media part 3 influence of the morphology of poly(l-lactic acid).J. Mat. Sci. 1(4), 198-206 (1990). (Pubitemid 21650015)
116. Li S, Garreau H, Vert M: Structure-property relationships in the case of the degradation of solid aliphatic poly-(α-hydroxy acids) in aqueous media. Part 1 Poly(dl-lactic acid).J. Mat. Sci. 1(3), 123 (1990).
117. Vert M, Li SM, Garreau H. Attempts to map the structure and degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J. Biomater. Sci. Polym. Ed. 6(7), 639-649 (1994).
118. Geng Y, Discher DE. Hydrolytic degradation of poly(ethylene oxide)-block-polycaprolactone worm micelles. J. Am. Chem. Soc. 127(37), 12780-12781 (2005). (Pubitemid 41339148)
119. Shih C. A graphical method for the determination of the mode of hydrolysis of biodegradable polymers. Pharm. Res. 12(12), 2036-2060 (1995).
120. Ahmed F, Pakunlu RI, Srinivas G et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol. Pharm. 3(3), 340-350 (2006). (Pubitemid 44021440)
121. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials 17(2), 103-114 (1996). (Pubitemid 26031366)
122. Li S, Molina I, Martinez MB, Vert M. Hydrolytic and enzymatic degradations of physically crosslinked hydrogels prepared from PLA/PEO/PLA triblock copolymers. J. Mater. Sci. Mater. Med. 13(1), 81-86 (2002). (Pubitemid 34145358)
123. MacDonald RT, McCarthy SP, Gross RA. Enzymatic degradability of poly(lactide): effects of chain stereochemistry and material crystallinity. Macromolecules 29(23), 7356-7361 (1996). (Pubitemid 126525583)
124. Tokiwa Y, Jarerat A. Biodegradation of poly(l-lactide).Biotechnol. Lett. 26(10), 771-777 (2004).
125. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268(1), 235-237 (1990). (Pubitemid 20233874)
126. Bermudez H, Brannan AK, Hammer DA, Bates FS, Discher DE. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules 35(21), 8203-8208 (2002). (Pubitemid 35173635)
127. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nano. 2(4), 249-255 (2007). (Pubitemid 46739812)
128. Bedu-Addo FK, Tang P, Xu Y, Huang L. Interaction of polyethyleneglycol- phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: sterically stabilized liposome formulations. Pharm. Res. 13(5), 718-724 (1996). (Pubitemid 26156220)
129. Koval M, Preiter K, Adles C, Stahl PD, Steinberg TH. Size of IgG-opsonized particles determines macrophage response during internalization. Exp. Cell Res. 242(1), 265-273 (1998). (Pubitemid 28366542)
130. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161(8), 4000-4007 (1998). (Pubitemid 28468977)
131. Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 448(1), 193-196 (1999). (Pubitemid 29151659)
132. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res. 26(1), 244-249 (2008).
133. Izumisawa T, Hattori Y, Date M, Toma K, Maitani Y. Cell line-dependent internalization pathways determine DNA transfection efficiency of decaarginine-PEG-lipid. Int. J. Pharm. 404(1-2), 264-270 (2010).
134. Shi F, Wasungu L, Nomden A et al. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem. J. 366(Pt 1), 333-341 (2002). (Pubitemid 34971834)
135. Aoki H, Fujita M, Sun CQ, Fuji K, Miyajima K. High-efficiency entrapment of superoxide dismutase into cationic liposomes containing synthetic aminoglycolipid. Chem. Pharm. Bull. 45(8), 1327-1331 (1997). (Pubitemid 27382729)
136. Atochina EN, Balyasnikova IV, Danilov SM, Granger DN, Fisher AB, Muzykantov VR. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am. J. Physiol. 275(4 Pt 1), L806-817 (1998).
137. Deneke SM. Thiol-based antioxidants. Curr. Top. Cell Regul. 36, 151-180 (2000).
138. Pedersen PJ, Adolph SK, Subramanian AK et al. Liposomal formulation of retinoids designed for enzyme triggered release. J. Med. Chem. 53(9), 3782-3792 (2010).
139. Trapasso E, Cosco D, Celia C, Fresta M, Paolino D. Retinoids: new use by innovative drug-delivery systems. Expert Opin. Drug Deliv. 6(5), 465-483 (2009).
140. Wegmann Jr, Krucker M, Bachmann S et al. Characterization of lycopene nanoparticles combining solid-state and suspended-state NMR spectroscopy. J. Agricult. Food Chem. 50(26), 7510-7514 (2002). (Pubitemid 35453708)
141. Palozza P, Muzzalupo R, Trombino S, Valdannini A, Picci N. Solubilization and stabilization of [beta]-carotene in niosomes: delivery to cultured cells. Chem. Phys. Lipids 139(1), 32-42 (2006). (Pubitemid 41796992)
142. Robb EL, Page MM, Wiens BE, Stuart JA. Molecular mechanisms of oxidative stress resistance induced by resveratrol: specific and progressive induction of MnSOD. Biochem. Biophys. Res. Comm. 367(2), 406-412 (2008).
143. Mignet N, Seguin J, Romano MR et al. Development of a liposomal formulation of the natural flavonoid fisetin. Int. J. Pharm. (2011) (In Press).
144. Yuan Z-p, Chen L-j, Fan L-y et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res. 12(10), 3193-3199 (2006).
145. Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int. J. Pharm. 404(1-2), 231-237 (2010).
146. Nilsson L, LoÌf̂ D, Bergenstãyhl Br. Phenolic acid nanoparticle formation in iron-containing aqueous solutions. J. Agricult. Food Chem. 56(23), 11453-11457 (2008).
147. Coimbra M, Isacchi B, van Bloois L et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm. (2011) (In Press).
148. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 390(1), 61-69 (2009).
149. Frozza RL, Bernardi A, Paese K et al. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol. 6(6), 694-703 (2011).
150. Lee W-C, Tsai T-H. Preparation and characterization of liposomal coenzyme Q10 for in vivo topical application. Int. J. Pharm. 395(1-2), 78-83 (2010).
151. Beg S, Javed S, Kohli K. Bioavailability enhancement of coenzyme Q10: an extensive review of patents. Recent Pat. Drug Deliv. Formul. 4(3), 245-255 (2010).
152. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev.61(6), 428-437 (2009).
153. Carnemolla R, Shuvaev VV, Muzykantov VR. Targeting antioxidant and antithrombotic biotherapeutics to endothelium. Semin. Thromb. Hemost. 36(3), 332-342 (2010).
154. Harush-Frenkel O, Altschuler Y, Benita S. Nanoparticle-cell interactions: drug delivery implications. Crit. Rev. Ther. Drug Carrier Syst. 25(6), 485-544 (2008).
155. Sun X, Zhang N. Cationic polymer optimization for efficient gene delivery. Mini Rev. Med. Chem. 10(2), 108-125 (2010).
156. Simone EA, Dziubla TD, Muzykantov VR. Polymeric carriers: role of geometry in drug delivery. Expert Opin. Drug Deliv. 5(12), 1283-1300 (2008).
157. Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp. Biol. Med. 236(1), 20-29 (2011).
158. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 7(4), 479-495 (2010).
159. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol. Life Sci. 66(17), 2873-2896 (2009).
160. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC).Adv. Drug Deliv. Rev. 48(2-3), 139-157 (2001). (Pubitemid 32434400)
161. Gao W, Chan JM, Farokhzad OC. pH Responsive nanoparticles for drug delivery. Mol. Pharm. 7(6), 1913-1920 (2010).
162. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 16(21), 2298-2307 (2010).